Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 4Triple Negative Breast Neoplasms 2Solid Tumor 2Neoplasms 2Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Advanced Solid Tumor 1Advanced Cancer 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × fluzoparib × Clear all
NCT03026881 2017-03-07

A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Recurrence, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡